Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors

NCT01837667 is registered in ClinicalTrials.gov with Lixte Biotechnology Holdings, Inc. as lead sponsor.

NCT NCT01837667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Lixte Biotechnology Holdings, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2013
Completion date
September 30, 2016
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neoplasms, tumors